Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Ixazomib is a second-generation proteasome inhibitor that has emerged as a pivotal therapeutic option for the treatment of multiple myeloma.What are the indications of Ixazomib?Ixa···【more】
Article source：Captain MedicineRelease date：2026-01-07Recommended：181
Ixazomib is a targeted, reversible proteasome inhibitor that has been approved for use in combination with lenalidomide and dexamethasone for the treatment of relapsed multiple mye···【more】
Article source：Captain MedicineRelease date：2026-01-07Recommended：202
Ixazomib is part of an all-oral treatment regimen. When used in combination with lenalidomide and dexamethasone, it provides a convenient treatment option for patients with multipl···【more】
Article source：Captain MedicineRelease date：2026-01-07Recommended：214
On September 9, 2015, Cambridge, Massachusetts, USA, and Osaka, Japan, announced that the U.S. Food and Drug Administration (FDA) had granted priority review status to the New Drug···【more】
Article source：Captain MedicineRelease date：2026-01-07Recommended：170
The U.S. Food and Drug Administration (FDA) approved ixazomib today for use in combination with two other therapies to treat patients with multiple myeloma who have received at lea···【more】
Article source：Captain MedicineRelease date：2026-01-07Recommended：180
Ivosidenib is available only with a doctor's prescription.Important Precautions for Ivosidenib UseIf you experience any changes in heart rhythm, contact your doctor immediately···【more】
Article source：Captain MedicineRelease date：2026-01-07Recommended：243
KRAS G12C mutation in non-small cell lung cancer and colorectal cancer【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：104
Larotrectinib is indicated for the treatment of adult and pediatric patients with solid tumors.【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：105
Non-small cell lung cancer【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：135
Gilteritinib is suitable for Leukemia.【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：109
Capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC).【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：216
Treatment of refractory relapsed multiple myeloma and certain types of diffuse large B-cell lymphoma.【more】
Article source：Captain MedicineRelease date：2026-01-06Recommended：165
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：[list:visits]2025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：[list:visits]2024-09-07
Lucius Pharmaceuticals Relocates from India to Laos: A Five-Year Development Journey of a Generic Dr···【more】
Recommended：[list:visits]2026-24-07
In recent years, Laos has gradually become a major global supply source for generic drugs, leveragin···【more】
Recommended：[list:visits]2026-22-07
Lucius version of Dacomitinib is now availableCutaneous adverse reactions and management strategies ···【more】
Recommended：[list:visits]2026-21-07
Company Overview: Industrial Migration from India to LaosLucius Pharmaceuticals (Laos) Co., Ltd. was···【more】
Recommended：[list:visits]2026-20-07
Lucius Pharmaceutical is one of the representative generic drug enterprises in Laos. The company was···【more】
Recommended：[list:visits]2026-17-07
Industrial Rise: From Zero to a "World Pharmacy" CandidateThe explosive growth of Laos'···【more】
Recommended：[list:visits]2026-16-07
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
